/ by UK HealthCare
The UK College of Pharmacy will host its ninth annual Therapeutics, Outcomes, Discovery & Delivery (TODD) Symposium. This event will host speakers and lead discussions on recent advances and new insights into diseases affecting the Commonwealth – including cancer, substance use disorders and cardiovascular diseases – as well as discoveries of therapeutics and diagnostics to address unmet clinical needs.
“The 2018 TODD Symposium will update the audience about recent advances in precision medicine and genomics to address significant clinical problems,” said Jeff Talbert, UK College of Pharmacy professor and chair of the 2018 TODD Symposium.
This year’s keynote speakers are Dr. William Douglas Figg Sr., the deputy chief of Genitourinary Malignancies Branch at the National Cancer Institute, and Dr. Atul Butte, the director of the Institute for Computational Health Sciences at the University of California, San Francisco.
Additional invited speakers include Precision Medicine Clinic director Dr. Jill Kolesar and Aprecia Pharmaceuticals CEO Tim Tracy.
A panel discussion titled “The Clinical Aspects of Precision Medicine” will include the following UK experts: UK Gill Heart & Vascular Institute director Dr. Susan Smyth, Precision Medicine director Dr. Jill Kolesar, Genomics Core Laboratory director Dr. Shulin Zhang and Department of Pathology & Laboratory Medicine chair Dr. C. Darrell Jennings.
The TODD Symposium will be held from 8 a.m. to 5:30 p.m. on Thursday, Sept. 6 in room 124 of the Lee T. Todd, Jr. Building.
All UK and regional scientific communities are welcome to attend the TODD Symposium. Registration is free and must be completed online by Sept. 3 to receive lunch.
Support for the symposium is provided by the UK Institute for Biomedical Informatics, UK Center for Clinical and Translational Science, UK Markey Cancer Center, the UK College of Pharmacy, and the UK College of Public Health.